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surcaslul ekctlve stating to n&c c&mary atcries with the 
Pnl~-&hntzballowex~dab~~t~t included suhacutethmm- 
bwir in 7 pplients (2.8*), myucardtrd htfarctii in 3 W7c1, 
death 3 (1.2%), urgent bypaw surgorr in 4 11.6%) and major 
bkcdtng cvmts in 24 (9.7%). Angiographie r&mia orcmmd im 
21 (20%) OT 103 ptiintr who mceiti a single se”,. 
Subgmup analysis, hcwevcr, rcvcaled that restenosis OF a 
Shtgk stall uccurrcd in 3 (7%) of 45 patients without prior 
Dnslaplasty cutnpwcd with B 127%) of 91 ptients with prim 
Vascular stats have been proposed by many invcsdgators 
(1.2) as a potential solution to abrupt vessel closure and 
resten& after coronary sngioplasty in humans. Direct 
ccmparison ofthe various stent designs with regard to safety 
and efficacy is not possible owing to the absence of side by 
side controlled studies. Because the techniques required to 
deliver these devices are rapidly evolving. such comparisons 
would bc m-cmaturc. The lawcst exuxience to date has been 
with the’ Palmaz-Schatz &rona;y stem developed by 
Johnson 8r Johnson interventional Systems and is ihe rub- 
ject of this report. 
Background 
Figure I illustrates the first balloon-expandable stem to 
undergo clinical trials in humans. This segmented tubular 
stent is made of stainless steel and is I .5 mm in diameter and 
15 mm in length. The walls me etched into multiple rows of 
staggered rectangles that allow for balloon expansion to a 
maximal diameter of 5 to 6 mm. This design represents a 
modification of the original rigid Palmaz stat design used 
successfully in a large series of patients with iliac a~cry 
stenos,s 13). 
Entry Criteria 
Patienta were enrolled prurpectively into this multicenter 
study on the basis of the ful!w.ing criteria: I) >7W% narrow- 
ing of a major native coronary ancry (22.5 but r5 mm in 
diameter: 2) lesion length rt5 mm Isin& stent): 3) symp_ 
turns of angina pectoris despite medical therapy or an 
abnormal thallium stress test with a defect in the distribution 
of the target vessel; 4) ability of the patient to give informed 
consent: and 51 patient S&IS as u &cd surgi& candidate. 
Patients were excluded if the target vessel WE extremely 
tortuous, the lesion was very distal or there was pea runoff. 
Patients wilh sapbenous vein bypass graft lesions were also 
excluded. as were patients with recent myocardiil infarction 
or abrupt vessel closure after routine angioplarty. Stenting 
of the left main coronary artery was considered a contmin- 
dication unless protected by one or more saphenous vein 
bypass gdts. 
Methods 
Parients were treated with a calcium channel blocker, 
aspirm and dipyridamole for 24 to 48 h before and for 3 
months alter stenting. Low molecular weight dextranilOwas 
given intravenously at IW ml/h for 2 h before stenting. then 
rd 50 to 100 ml/h until I liter was infused; IO.OtXJ U ofhewitt 
was given during the procedure, followed by additional 
doses to maintain the activated clotting time at 300 s. After 
iin initial pilot study (41 in 39 patients. all patients in the 
series were treated with warfarin for I to 3 months after the 
procedure. All films were sent tu a central sore laboratory 
for quantitative analysis. 
Results 
Patients. Two hundred forty-seven patients were en- 
rolled in the study prospectively (192 men and 55 women). 
The average age of the patients was 56 years (range 27 to 86). 
In 70% of the patients r&renosis had occurred after previous 
balloon angioplarty. The stated vessels were the righ: 
coronary artery in 134 patients, left anterior descending 
artery in 78, circumflex/obtuse marginal branch 31 and left 
main artery in 4. One hundred ninety-eight patients received 
a single stem and 49 received two to six stats in tandem. 
St&t delivery sucwzss. Stem delivery was successful in 
94% or the patients. The outcome of those patients with 
failed stat delivery has been reported previously (5). Stat 
delivery SUCCESS has improved to >99% with the introduc. 
tion ofa 5F subselective sheath (T&guide, Schneider). This 
device prevents stent-wall contact until deployment of the 
stent and thus eliminates snagging and embolization, both 
previously reported (4) as complications in a small percent of 
patients. This report focuses on the clinical outcome of those 
patients in whom stent delivery was successful. Results of 
the pilot study without anticoagulant herapy in 39 patients 
were also previously reported (5) and are excluded from this 
analysis. 
Complications. Table 1 describes the complications that 
Tabte 1. Complicarions After Coronary Stenting in 247 Patienls 
No % 
occurred in the 247 patients in whom stat delivery was 
successful and who underwent anticoagulant therapy. Acute 
closure defined as total stat thrombosis within 24 h of stent 
delivery did not occur. Subacute thrombosis defined as total 
stent thrombosis between 24 h and 2 weeks occurred in 
seven patients (2.8%). Of these seven patients, one devel- 
oped Q wave myocardial infarction and two developed 
non-Q wave myocardial infarction. Urgent bypass surgery 
was required for guiding catheter or wire dissection in three 
pstients or subacute closure in one patient. There were no 
de&s related to stat thrombosis. but there was one cere- 
brovascular accident 2 months after the procedure, one 
sudden death at 4 months in a patient with a normal stress 
test and and one malignancy-related eath with no angina at 
2 years. 
Major bleeding eon~pkcuions requiring either transfusion 
or surgical repair occurred in 24 patients (9.7%). Therefore a 
major complication such as death, myocardial infarction or 
urgent bypass surgery occurred in Ill patients (4%). 
Restentis. Angiographic restenosis defined as SXJ% 
narrowing within the stem occurred in 20% of the patients 
who received a single stem and SO% of the patients who 
received two to six stats. Clinical restenosis defined as 
narrowing in the stat sufiicient to cause symptoms or B 
positive exercise stress test and requiring either coronary 
angiop!nny or bypass surgery (in the absence of collateral 
vessels) occurred in approximately 50% of the patients with 
a single stat. Restenosis detittd as ~0.72 mm of itttimal 
hypaplasia (6) occurred in 50% of these patients. 
Angiography at t year in 31 patients (Table 2) revealed no 
change in minimal stent lumen diameter compared with that 
at 6 month angiography (1.88 -C 0.64 versus I.% C 0.69 mm) 
(Savage M. personal communication). The influence of prior 
restenosis after angioplasty on stem restettosis is seen in 
Table 3 (Teirslein P. personal communication). Overmi, 
patients who received a single stem at the time of their first 
angioplasty procedure had a restenosis rate of 18% com- 
pared with a rate of 34% in those patients who had a prior 
balloon angiaplasty procedure. If the group is analyzed with 
respect o single versus multiple stents (Table 4). restenosis 
occurred in 7% and 45%. respectively. Conversely, patients 
with prior restenosis who received a single stent developed 
angiographic restenosis 21% of the rime compared with 44% 
in those who received niult~ple 5tcnt5 ITable 4). 
A subgroup of 98 patients in those whose coronary 
angioplasty procedure resuited in a suboptimal angiogmphrc 
result (defined as the prestxc of a dissection, filling defect 
of residual 250% na~owing) was analyzed with r&d to 
complication5 (Table 5) aad restenosis (Table 6). Acute 
closure was absent. but subacute closure occurred in four 
patients, thus accounting for the majority of thmmbotic 
events within the entire n&s. There were no deaths, but 
myocatdial infarction UT urgent bypass graft surgery oc- 
curred in five patients (5.1%). 
The angiogmphic restenosis rate in tine 56 oatients avail- 
able for angimraphic follow-up study was 15% (7 of 46i in 
patients with a single stcnt and 70% (7 of IO) il patients who 
received muhiple 5tcnt5. Clinical restenosis occurred in 
4.3% (2 of 46) and 40% (4 of 10) in those groups. rcspec- 
tively. An example of aogiographic outcome titer coronary 
stealing is seen in Figure 2. 
DiScuSsiall 
Tbmmbosis &or 5tcttt impkantatiott. Both restcnosis and 
abrupt vessel closure continue to bc the two mo5t limiting 
factors in cwonary balloon angioplasly (7-12). Abrupt clo- 
sure is generally a result of thrombosis, spasm or dissection 
atter angioplasty. Thus, two of the three causes of abrupt 
closwc arc mechanical, swestine that a mechanical ores 
thesis may soive this problem. Tacking up flap5 and improv- 
ina the flow lield tow affect thrombosis favorablv: bowever. 
th& salutary effe& of stenting arc otTset by ihe inherent 
thromhogenicity of most metals. Surface treatments such as 
polishing and administration of antiplatelet medications and 
anticoagulant agents appear to solve the immediate throm- 
bosis problem, but they do not eliminate delayed thrombo- 
sir. This complication introduces a ocw risk compared with 
routine angioplasty because it may occur after hospital 
discharge. Surface coatings with drugs such as heparin. 
hirudin or inonoclonal andbodies to specific platckt factor5 
may substantially reduce this rerious complication in the 
future. 
Rertcnmis &cr slcnt iop!mtlation. Whether 5tcot5 re- 
duce rcstenosis after angioplasty can only be answered by 
carefully planned. randomized. controlled studies that arc 
forthcoming. Until these data arc available, one can con‘ 
elude from out- work that at least in a cuefully selected 
group of patients who would otherwise be at high risk for 
restenoG5 (70% of our patients have already had at last one 
unsuccessful aogioplasty procedure). a nstenosis rate of 
ZG’+Z seems encouraging. Marc relevant though is the rc. 
duced clinical failure ralc. which is best ondcrawd if one 
analyzes quantification of intimal hypcrplasia within the 
stat. Seriuys et al. (6) generated a definition of rcstenoris 
based on 0.72 mm of intimal growth within the stem (Wall- 
stent). By this definition. SW of our patients with a single 
stent developed rateoasis. However. if rcstenosis is defined 
as 250% htmind narrowing. only 20% of the same patients 
develop rcstcnosis. This ohservalion suggests that the 5Icot 
does not inhibit smooth muscle cell growth; rather it pro- 
vides an optimal initial luotinal diameter 50 that the urual 
mtimal hyperplasia does M)I compromise the vessel lumen 
b) >5C%. More intriguing. however. is the observation that 
prior restenosis appcar~ to increase the likelihood of stat 
rester&s. Experimental models (131 have doeumcnled in- 
creased smooth mwcle cell tomover when endolhelial cell 
cultures arc exposed to cyclical trauma. One can speculate 
that multiple angioplasty procedures predispose the target 
lesion to increased smooth muscIc cell gmwlh despite an 
optimal initilll lumioal diameter provided by the stat and 
that perhaps the stat should lx placed during the inilial 
angioplarfy procedure. 
Ellis et al. (14) provided funher evidence that an optimal 
initial Went luminal diameter is critical to prevent restenosis. 
In an analysis of patients with a single stcnt, angioyaphic 
reslcnosis occurred in only 14% of those who left the 
Tat& 6. Rertemsis After Stenting in 56 Palicnts Afw Suboprimal 
Coronary Anglopklsty Besub 
smgk SW”, MUItIpk Sle”l5 

laboratory with a stent luminal stenosis <IO% whereas it 
occurred in 25% of those patients with a final stem luminal 
stenosis >lO%. 
Neointinal proliferation at I year angiagraphic ioUow.up. 
The healing process of the stem is well documented m 
animal models !!:I and appears IO be complete by 4 to 6 
months. After initial fibrin and platelet deposition. fibroblart 
proliferation seems to peak at approximstely 8 weeks. There 
is gradual thinning of the neointima as the previously cellular 
infiltrate is replaced with acellular ground substance by 6 to 
8 months. Angiagraphy at I year in 31 patients in ou, series 
appears to confirm that the biologtc response to thew 
implants is similar in that there is no progression of intimal 
hypaplasia after 6 months. 
Future developments. The limitations of the Palma- 
Schatz coronary stat suggest he future directions of coro- 
nary stenti.w. Subacute thrombosts remains a serious threat 
to the ubiquitous application of stetttr in small vessels and 
much research is king conducted to attempt to eliminate 
this complication by developing coatings such as hepxin. 
hintdin or monoclooal antibodies to specific platelet factors. 
Pharmacologic agents to inhibit smooth muscle cell growth 
may also be added to stem coatings in an effort to decrease 
the rate of restenosis by administering high doses of medi- 
cations directly to the target site. 
Rodioluroncy of the S~PIZI remnins n problem that may 
prevent accttrate delivery and placement of the stem. Sev- 
eral new metals that will enhance the ability of the apemto, 
to see the device during placement are being developed. The 
results of a balloon-expandable stent made of tantalum have 
been previously reported (16). 
Conclusions 
Despite the absence of randomized controlled studies. 
this initial report of coronary sleeting provides come insight 
into e.sciti.lg new technology that may have a great impact 
on coronary angioplasty in tlte future. On the basis of these 
preliminary observations. it is reasonable to conclude that I) 
stems can be safely delivered in X8% of cases; 2) PCL)IC 
closure due lo stent thrombosis within the Is1 24 h does not 
occu,; 3) subacute thrombosis may occo, within the Is1 2 
weeks despite anticoagulant therapy in a small percentage of 
patients; 4) stenting after previous suboptimal angioplasty 
results may be responsible for most subacute thrombosis 
eveds. suggesting that patients with 2 poor angioplaw 
outcome may require adjunctive therapy with tlimmbolyris 
at the time of stenting or perhaps during the postoperative 
in pat,mtr who receive a single rtent. especially in those 
who receive a stem at the time of the first angioplasty 
procedure: and 61 insenion of multiple stems results in 
restenosir ,ates similar to those of angioplasry and rhus is 
not advised ontd custom stems of variable lengths become 
available 
It is huped that with continuing research. futu;e ~tent 
design will allow us to conclude that vascular stenting is both 
a safe and etTcctive approach to the treatment of abrupt 
vessel closure and restenosis in selected patients undergoing 
coronary angioplasty. 
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